Sihuan Pharmaceutical Gets Hong Kong Approval for Two Injectable Aesthetic Products

MT Newswires Live
10/20

Sihuan Pharmaceutical (HKG:0460) said two self-developed injectable aesthetic products made by its subsidiary Meiyan Space Biotechnology have been approved for market launch in Hong Kong.

The products are a polycaprolactone microsphere facial filler, available in 0.5-mL, 1.0-mL and 2.0-mL tubes, and a hyaluronic acid sodium composite skin booster, available in multiple sizes ranging from 0.5 mL to 3.0 mL, as well as a 5-mL package containing two 2.5-mL tubes, according to a Tuesday Hong Kong exchange filing.

The facial filler uses a polycaprolactone gel carrier to provide immediate filling and improve facial depressions. The skin booster contains L-carnosine and is designed to hydrate and moisturize skin, with antioxidant, anti-glycation and anti-inflammatory effects, the company said.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10